The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: The predictive value of biochemical markers of bone turnover

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 2, 1998, Pages 333-338

  Amama, Ernest A ^a   Taga, Michiyoshi ^a   Minaguchi, Hiroshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; BUSERELIN; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; GONADORELIN AGONIST; GOSERELIN; HYDROXYPROLINE; OSTEOCALCIN; PYRIDINOLINE;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERALIZATION; BONE TURNOVER; CLINICAL TRIAL; ENDOMETRIOSIS; FEMALE; HUMAN; LEIOMYOMA; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031732752     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.2.4565     Document Type: Article

References (45)

1. Lemay A, Maheux R, Huot C, Blanchet J, Faure N. 1988 Efficacy of intranasal or subcutaneous luteiruzing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol. 158:233-236.
2. Faure N, Lemay A. 1987 Ovarian suppression in polycystic ovarian disease during 6 months administration of a luteinizing hormone-releasing hormone (LHRH) agonist. Clin Endocrinol (Oxf) 27:703-713.
3. Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas ATA. 1985 Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study. Am J Obstet Gynecol. 152:1034-1038.
4. Meldrum DR, Chang RJ, Lu J, Vale W, Rivier J, Judd HL. 1982 "Medical oophorectomy" using a long-acting GnRH agonist-possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab. 54:1081-1083.
5. Canne CE, Henzl M, Burry K, et al. 1987 Reversible bone loss is produced by the GnRH agonist nafarelin. In: Cohn DV, Martin TJ, Meunier PJ, eds. Calcium regulation and bone metabolism: basic and clinical aspects. Vol 9. Amsterdam: Elsevier Science Publishers B.V.; 123-127.
6. Lemay A, Surrey ES, Friedman AJ. 1994 Extending the use of gonadotropin-releasing hormone agonist: the emerging role of steroidal and nonsteroidal agents. Fertil Steril. 61:21-34.
7. Delmas PD. 1991 Biochemical markers of bone turnover: methodology and clinical use in osteoporosis. Am J Med. [Suppl 5B]91:59S-63S.
8. Aloia JF, Cohn SH, Zanzi I, Abesamis C, Ellis K. 1978 Hydroxyproline peptides and bone mass in postmenopausal and osteoporotic women. J Clin Endocrinol Metab. 47:314-318.
9. Lauffenburger T, Olah AJ, Dambacher MA, Guncaga J, Lentner C, Haas HG. 1977 Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's disease. Metabolism. 26:589-606.
10. Nordin BE. 1978 Diagnostic procedures in disorders of calcium metabolism. Clin Endocrinol (Oxf) 8:55-67.
11. Marshall LA, Cain DF, Dmowski WP, Chesnut III CH. 1996 Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstet Gynecol. 87:350-354.
12. Eyre D. 1992 Editorial: new biomarkers of bone resorption. J Clin Endocrinol Metab. 74:470A-470C.
13. Seibel MJ, Woitge H, Scheidt-Nave C, et al. 1994 Urinary hydroxypyridinium cross-links of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res. 9:1433-1440.
14. Body JJ. Delmas PD. 1992 Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hvpercalcemia. J Clin Endocrinol Metab. 74:471-475.
15. Coleman RE, Houston S, James I, Rodger A, Rubens RD, Leonard RCF. 1992 Preliminary results of the use of urinary excretion of pyridinium cross-links for monitoring metastatic bone disease. Br J Cancer. 65:766-768.
16. Rosen HN, Dresner-Pollak R, Moses AC, et al. 1994 Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int. 54:26-29.
17. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. 1992 A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 7:1251-1258.
18. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1693-1700.
19. Gertz BJ, Shao P, Hanson DA, et al. 1994 Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res. 9:135-142.
20. Campodarve I, Ulrich U, Bell N, et al. 1995 Urinary N-telopeptide of type I collagen monitors bone resorption and may predict change in bone mass of the spine in response to hormone replacement therapy. J Bone Miner Res. [Suppl]10:S182.
21. Garnero P, Gineyts E, Riou JP, Delmas PD. 1994 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab. 79:780-785.
22. Ebeling PR, Atley LM, Guthrie JR, et al. 1996 Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab. 81:3366-3371.
23. Dmowski WP, Rana N, Pepping P, Cain DF, Clay TH. 1996 Excretion of urinary N-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss. Fertil Steril. 66:929-936.
24. Rosen CJ, Chesnut III CH, Mallinak NJ. 1997 The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 82:1904-1910.
25. Chesnut III CH, Bell NH, Clark GS, et al. 1997 Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 102:29-37.
26. Bonde M, Fledelius C, Qvist P, Christiansen C. 1996 Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin Chem. 42:1639-1644.
27. Garnero P, Hausherr E, Chapuy MC, et al. 1996 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res. 11:1531-1538.
28. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. 1990 Urinary excretion of pvridinium cross-links: a new marker of bone resorption in metabolic bone disease. Bone Miner. 8:87-96.
29. Emmi AM. 1993 The use of GnRH agonist in the medical therapy of endometriosis in the woman with pain. Semin Reprod Endocrinol. 11:119-126.
30. Friedman AJ. 1993 Treatment of uterine myomas with GnRH agonist. Semin Reprod Endocrinol. 11:154-161.
31. Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C. 1988 The effect of a gonadotropin-releasing hormone agonist analog (Nafarelin) on bone metabolism. J Clin Endocrinol Metab. 67:701-706.
32. Whitehouse RW, Adams JE, Bancroft K, Vaughan-Williams CA, Elstein M. 1990 The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clin Endocrinol (Oxf). 33:365-373.
33. Dawood MY, Lewis V, Ramos J. 1989 Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril. 52:21-26.
34. Gudmundsson JA, Ljunghall S, Bergquist C, Wide L, Nillius SJ. 1987 Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition. J Clin Endocrinol Metab. 65:159-163.
35. Steingold KA, Cedars M, Lu JKH, Randle D, Judd HL, Meldrum DR. 1987 Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol. 69:403-411.
36. van Leusden HA, Doglerom AA. 1988 Rapid reduction of uterine leiomyoma with monthly injection of D-Trp6-GnRH. Gynecol Endocrinol. 2:45-51.
37. Slemenda CW, Hui SL, Longcope C, Wellman H, Johnston CC. 1990 Predictors of bone mass in perimenopausal women. A prospective study of clinical data using photon absorptiometry. Ann Intern Med. 112:96-101.
38. Hansen MA, Overgaard K, Riis BJ, Christiansen C. 1991 Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. Br Med J. 303:961-964.
39. Kushida K, Takahashi M, Kawana K, Inoue T. 1995 Comparison of markers for bone formation and resorption in premenopansal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab. 80:2447-2450.
40. Taga M, Minaguchi H. 1996 Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstet Gynecol Scand. 75:162-165.
41. Riis BJ, Christiansen C, Johansen JS, Jacobson J. 1990 Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonist? J Clin Endocrinol Metab. 70:920-924.
42. Eldred JM, Haynes PJ, Thomas EJ. 1992 A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone. Clin Endocrinol (Oxf) 37:354-359.
43. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med. 331:1618-1623.
44. Christiansen C, Riis BJ, Rodbro P. 1987 Prediction of rapid bone loss in postmenopausal women. Lancet. 16:1105-1107.
45. Bonde M, Gamero P, Fledelius C, Qvist P, Delmas PD, Christiansen C. 1997 Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res. 12:1028-1034.